418 related articles for article (PubMed ID: 8590163)
1. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
5. Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum.
Grabowski P; Schönfelder J; Ahnert-Hilger G; Foss HD; Heine B; Schindler I; Stein H; Berger G; Zeitz M; Scherübl H
Virchows Arch; 2002 Sep; 441(3):256-63. PubMed ID: 12242522
[TBL] [Abstract][Full Text] [Related]
6. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies.
Syversen U; Opsjøn SL; Stridsberg M; Sandvik AK; Dimaline R; Tingulstad S; Arntzen KJ; Brenna E; Waldum HL
J Clin Endocrinol Metab; 1996 Dec; 81(12):4470-5. PubMed ID: 8954061
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance.
Hong SM; Kim MJ; Pi DY; Jo D; Yu E; Ro JY
Hum Pathol; 2005 Jul; 36(7):732-40. PubMed ID: 16084941
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma.
Edgren M; Stridsberg M; Kalknar KM; Nilsson S
Anticancer Res; 1996; 16(6B):3871-4. PubMed ID: 9042273
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of elevated serum chromogranin A levels.
Syversen U; Ramstad H; Gamme K; Qvigstad G; Falkmer S; Waldum HL
Scand J Gastroenterol; 2004 Oct; 39(10):969-73. PubMed ID: 15513336
[TBL] [Abstract][Full Text] [Related]
14. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
15. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin.
Gazdar AF; Helman LJ; Israel MA; Russell EK; Linnoila RI; Mulshine JL; Schuller HM; Park JG
Cancer Res; 1988 Jul; 48(14):4078-82. PubMed ID: 3383200
[TBL] [Abstract][Full Text] [Related]
16. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
[TBL] [Abstract][Full Text] [Related]
17. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
19. Expression of neuroendocrine markers in non-small cell lung cancer.
Sørhaug S; Steinshamn S; Haaverstad R; Nordrum IS; Martinsen TC; Waldum HL
APMIS; 2007 Feb; 115(2):152-63. PubMed ID: 17295682
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
